Fan, Bin
Dai, David
DiNardo, Courtney D.
Stein, Eytan
de Botton, Stéphane
Attar, Eyal C.
Liu, Hua
Liu, Guowen
Lemieux, Ian
Agresta, Samuel V.
Yang, Hua
Funding for this research was provided by:
Agios Pharmaceuticals, Inc
Article History
Received: 1 October 2019
Accepted: 24 March 2020
First Online: 15 April 2020
Compliance with ethical standards
:
: BF, HL, GL, IL, and HY are employees of Agios Pharmaceuticals, Inc. DD, ECA, and SVA were employees of Agios at the time of the study. BF, ECA, HL, GL, IL, SVA, and HY hold stock options in Agios. ECA is a consultant to Advance Medical and is currently an employee of Aprea Therapeutics. SVA is currently an employee of Infinity Pharmaceuticals. CDD is a consultant/advisor to AbbVie, Agios, Celgene, and Notable Labs and has received honoraria from AbbVie, Agios, Celgene, Jazz, Syros, and Daiichi Sankyo. ES has stock/ownership of Auron Therapeutics; is a consultant/advisor to AbbVie, Agios, Astellas, Bayer, BioLineRx, Celgene, Daiichi Sankyo, Genentech, Novartis, Pfizer, PTC Therapeutics, and Syros; has received research funding from Agios, Amgen, Bayer, Celgene, and Syros; and has received travel expenses from Abbvie, Astellas Pharma, Celgene, Daiichi Sankyo, Novartis, and Syros. SdB is a consultant/advisor to Agios, Bayer, Carthagenetics, Celgene, FORMA Therapeutics, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; has attended speaker’s bureau and received honoraria from AbbVie; has received honoraria and travel expenses from Agios, Carthagenetics, Celgene, FORMA Therapeutics, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; has received honoraria from Bayer; and has received research funding from Agios.
: The study was conducted according to the International Conference for Harmonization Good Clinical Practice guidance and in accordance with the principles of the Declaration of Helsinki. The study was approved by independent ethics committees.
: All patients provided written informed consent prior to participation.